Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Pittaro

Clinical Cardiac Electrophysiology Stamford, CT Medical Doctor

NPI 1891806857 CMS profile 222141

1177 Summer St, 5Th Floor, Stamford, CT 06905

Open in the dashboard

General payments

$69,588

192 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$8,677 paid to institutions, not to them · program years 2019–2020

Through program year 2025, Michael Pittaro of Stamford, CT is reported in the CMS Open Payments database as having received $69,588 across 192 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $8,677 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 82nd percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $439 14
2024 General $8,374 22
2023 General $628 15
2022 General $12,678 24
2021 General $21,108 12
2020 General $10,118 21
2019 General $16,244 84

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Pittaro
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Michael Pittaro were reported at $439. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Michael Pittaro Clinical Cardiac Electrophysiology median Middle half National median
2019 $16,244 $2,361 $585–$8,260 $163
2020 $10,118 $993 $247–$4,351 $114
2021 $21,108 $1,185 $326–$4,739 $132
2022 $12,678 $2,073 $554–$6,789 $149
2023 $628 $2,568 $759–$8,159 $160
2024 $8,374 $2,557 $703–$7,403 $164
2025 $439 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $66,665 70 payments
  2. Medtronic, Inc. $779 12 payments
  3. Novartis Pharmaceuticals Corporation $626 37 payments
  4. Biosense Webster, Inc. $391 15 payments
  5. Janssen Pharmaceuticals, Inc $210 14 payments
  6. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $128 7 payments
  7. Edwards Lifesciences Corporation $114 1 payment
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $82 4 payments
  9. E.R. Squibb & Sons, L.L.C. $71 5 payments
  10. Acutus Medical, Inc. $70 4 payments
  11. Other $450 23 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $66,548 64 payments
  2. Food and Beverage $2,614 124 payments
  3. Travel and Lodging $421 3 payments
  4. Education $5 1 payment
Products named General payments · program years 2019–2025
  1. Accent Pacemaker Cardiac Rhythm Management $19,019 6 payments
  2. ALLURE $9,138 10 payments
  3. Assurity Pacemaker $8,888 15 payments
  4. ACCENT $8,500 10 payments
  5. Endurity Pacemaker $6,392 6 payments
  6. Accent Pacemaker Cardiac Arrhythmias and Heart Failure $4,280 5 payments
  7. Quadra Allure MP RF CRT Pacemkr $2,340 3 payments
  8. Unify Assura CRT Defibrillator $1,712 1 payment
  9. Absorb GT1 $1,700 1 payment
  10. Fortify Assura, Ellipse ICD $1,605 3 payments
  11. Other $5,694 137 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 29 drugs

Part D claims

1,629

Median for Cardiology: 2,533

Drug cost

$603,545

Median for Cardiology: $485,213

Branded share of claims

32.2%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 295 $388,963
Entresto Sacubitril/Valsartan Brand 74 $127,675
Xarelto Rivaroxaban Brand 29 $37,230
Farxiga Dapagliflozin Propanediol Brand 15 $17,556
Jardiance Empagliflozin Brand 11 $12,418
Amiodarone Hcl Generic 100 $3,319
Metoprolol Succinate Generic 188 $2,893
Dofetilide Generic 19 $2,838
Flecainide Acetate Generic 48 $2,152
Atorvastatin Calcium Generic 190 $1,915

The 10 drugs with the highest cost, of 29 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 63 billing codes

Paid by Medicare

$248,178

Medicare's payments for the services billed

Medicare patients

867

Average age 80

Services billed

4,184

393 women, 474 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 61%
Ischemic heart disease 51%
Arthritis 50%
Heart failure 48%
Chronic kidney disease 35%
Diabetes 32%
Depression 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LEQVIO
  • Novartis Pharmaceuticals Corporation $77
$77 — —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $54
$54 74 —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $26
$26 11 —
Arcalyst
  • Kiniksa Pharmaceuticals International, plc $24
$24 — —
NEXLETOL
  • Esperion Therapeutics, Inc. $24
$24 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

192 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in Connecticut

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record